LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
![Foto de LUIS GONZAGA](/img/nophoto.png)
![Foto de KU Leuven](/img/noimage_org.png)
KU Leuven
Lovaina, BélgicaPublicaciones en colaboración con investigadores/as de KU Leuven (23)
2024
2023
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
The Lancet, Vol. 401, Núm. 10378, pp. 733-746
2022
-
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
npj Breast Cancer, Vol. 8, Núm. 1
-
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487
-
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311
-
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
Scientific Reports, Vol. 12, Núm. 1
2021
-
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867
2020
-
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
Journal of Thoracic Oncology, Vol. 15, Núm. 5, pp. 709-740
2019
-
Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119
2018
-
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
The Lancet Oncology, Vol. 19, Núm. 4, pp. 521-536
-
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Clinical Lung Cancer, Vol. 19, Núm. 4, pp. 331-339
2017
2015
-
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer
Annals of Oncology, Vol. 26, Núm. 8, pp. 1573-1588
-
A Phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
Clinical Cancer Research, Vol. 21, Núm. 4, pp. 730-738
2014
-
2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease
Annals of Oncology, Vol. 25, Núm. 8, pp. 1475-1484
-
2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
Annals of Oncology, Vol. 25, Núm. 8, pp. 1462-1474
-
Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer
Annals of Oncology, Vol. 25, Núm. 9, pp. 1681-1690
2013
-
Strategies for improving outcomes in NSCLC: A look to the future
Lung Cancer, Vol. 82, Núm. 3, pp. 375-382
2012
-
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
Clinical Cancer Research, Vol. 18, Núm. 11, pp. 3170-3179
-
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer
Journal of Clinical Oncology, Vol. 30, Núm. 25, pp. 3084-3092